ARIZ announces Seed round funding

November 3, 2020

ARIZ Precision Medicine, The PRDM Oncogene Targeting Company™ announced that it has secured seed financing bringing total funding to date of $2.5 million. Proceeds will be used to expand the management team as well as continue development of its proprietary PRDM-based product candidates for lung cancer, as well as ovarian, breast, and gastric cancers, and multiple myeloma.